UAE- The Abu Dhabi Department of Health and Takeda Pharmaceuticals have signed a Memorandum of Understanding (MoU) to advance research in rare diseases and oncology.
This strategic partnership aims to establish a framework for collaboration to enhance research endeavors in these critical medical fields.
The alliance will focus on several key initiatives to boost clinical research and innovation and facilitate regional advisory boards with expert panels.
These panels will facilitate knowledge sharing, address healthcare gaps, and propose solutions to improve patient outcomes.
One of the partnership’s primary objectives is to develop regional treatment guidelines and consensus statements, ensuring evidence-based practices are widely adopted and ultimately improving patient care across the region.
Additionally, the partners will generate comprehensive data on the region’s epidemiology of rare diseases and oncology to identify and address unmet medical needs in these areas.
The collaboration will also integrate innovative Patient Support Programs (PSPs) into Abu Dhabi’s healthcare ecosystem, leveraging Takeda’s global experience and best practices.
These programs will be tailored to the specific needs of rare disease patients, aiming to improve treatment adherence, quality of life, and overall patient outcomes.
The partnership will also witness the launch of joint public awareness campaigns to educate the public on the importance of early diagnosis and the recognition of rare disease signs and symptoms.
Furthermore, partnerships between local healthcare providers in both countries will foster educational programs for professionals, focusing on cutting-edge diagnostic tools and techniques.
The partnership was signed during the BIO International Convention 2024 in San Diego, USA, in the presence of Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health—Abu Dhabi, Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre at DoH, and Dr. Ahmed Fayed, General Manager of the East Gulf & Levant Cluster at Takeda.
Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre at the Department of Health – Abu Dhabi (DoH), emphasized the significance of the partnership, stating, “Rare diseases affect over 300 million people globally, and cancer remains a leading cause of death globally, accounting for nearly 10 million deaths in 2020 alone.”
Dr. Asma Ibrahim Al Mannaei further stated that the Department will collaborate with Takeda Pharmaceuticals to unite efforts and leverage diverse expertise and resources to collectively lead groundbreaking discoveries and improve patient treatment options as part of its commitment to address global health challenges.
Dr. Ahmed Fayed, General Manager of East Gulf & Levant at Takeda, added, “Our mission as Takeda is to strive towards a ‘Better Health and a Brighter Future for the people worldwide’ through leading innovation in medicine. Currently, we are witnessing the Department of Health – Abu Dhabi spearheading a transformative movement in the healthcare landscape, particularly in rare diseases.”
This strategic partnership between DoH and Takeda Pharmaceuticals holds immense promise for advancing healthcare in Abu Dhabi and the wider region.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook
